Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Nov;37(11):2490–2492. doi: 10.1128/aac.37.11.2490

Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies.

C Lumbreras 1, J R Otero 1, J A Herrero 1, R Gomez 1, M Lizasoain 1, J M Aguado 1, F Colina 1, I Garcia 1, E Moreno 1, A R Noriega 1
PMCID: PMC192416  PMID: 8285641

Abstract

The efficacy of ganciclovir, given prophylactically, to prevent cytomegalovirus-related disease was evaluated in liver transplant recipients, mostly seropositive, under treatment with OKT3 monoclonal antibodies. The incidence of cytomegalovirus disease and visceral involvement was reduced, respectively, from 52 and 36% in the control group to 12 and 8% in the ganciclovir-treated patients. Leukopenia was a frequent (32%) side effect of ganciclovir administration.

Full text

PDF
2490

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balfour H. H., Jr, Chace B. A., Stapleton J. T., Simmons R. L., Fryd D. S. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med. 1989 May 25;320(21):1381–1387. doi: 10.1056/NEJM198905253202105. [DOI] [PubMed] [Google Scholar]
  2. Bell R., Sheil A. G., McDonald J. A., McCaughan G. W. The role of CMV immune prophylaxis in patients at risk of primary CMV infection following orthotopic liver transplantation. Transplant Proc. 1989 Oct;21(5):3781–3782. [PubMed] [Google Scholar]
  3. Drew W. L., Miner R. C., Busch D. F., Follansbee S. E., Gullett J., Mehalko S. G., Gordon S. M., Owen W. F., Jr, Matthews T. R., Buhles W. C. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis. 1991 Apr;163(4):716–719. doi: 10.1093/infdis/163.4.716. [DOI] [PubMed] [Google Scholar]
  4. Dussaix E., Wood C. Cytomegalovirus infection in pediatric liver recipients. A virological survey and prophylaxis with CMV immune globulin and early DHPG treatment. Transplantation. 1989 Aug;48(2):272–274. [PubMed] [Google Scholar]
  5. Freise C. E., Pons V., Lake J., Burke E., Ascher N. L., Roberts J. P. Comparison of three regimens for cytomegalovirus prophylaxis in 147 liver transplant recipients. Transplant Proc. 1991 Feb;23(1 Pt 2):1498–1500. [PubMed] [Google Scholar]
  6. Gleaves C. A., Smith T. F., Shuster E. A., Pearson G. R. Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens. J Clin Microbiol. 1985 Feb;21(2):217–221. doi: 10.1128/jcm.21.2.217-221.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Grattan M. T., Moreno-Cabral C. E., Starnes V. A., Oyer P. E., Stinson E. B., Shumway N. E. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 1989 Jun 23;261(24):3561–3566. [PubMed] [Google Scholar]
  8. Hibberd P. L., Tolkoff-Rubin N. E., Cosimi A. B., Schooley R. T., Isaacson D., Doran M., Delvecchio A., Delmonico F. L., Auchincloss H., Jr, Rubin R. H. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation. 1992 Jan;53(1):68–72. doi: 10.1097/00007890-199201000-00013. [DOI] [PubMed] [Google Scholar]
  9. Merigan T. C., Renlund D. G., Keay S., Bristow M. R., Starnes V., O'Connell J. B., Resta S., Dunn D., Gamberg P., Ratkovec R. M. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med. 1992 Apr 30;326(18):1182–1186. doi: 10.1056/NEJM199204303261803. [DOI] [PubMed] [Google Scholar]
  10. O'Grady J. G., Alexander G. J., Sutherland S., Donaldson P. T., Harvey F., Portmann B., Calne R. Y., Williams R. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet. 1988 Aug 6;2(8606):302–305. doi: 10.1016/s0140-6736(88)92356-2. [DOI] [PubMed] [Google Scholar]
  11. Paya C. V., Hermans P. E., Wiesner R. H., Ludwig J., Smith T. F., Rakela J., Krom R. A. Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations. J Infect Dis. 1989 Nov;160(5):752–758. doi: 10.1093/infdis/160.5.752. [DOI] [PubMed] [Google Scholar]
  12. Rubin R. H. Preemptive therapy in immunocompromised hosts. N Engl J Med. 1991 Apr 11;324(15):1057–1059. doi: 10.1056/NEJM199104113241509. [DOI] [PubMed] [Google Scholar]
  13. Saliba F., Gugenheim J., Samuel D., Bismuth A., Mathieu D., Serres C., Bismuth H. Incidence of cytomegalovirus infection and effects of cytomegalovirus immune globulin prophylaxis after orthotopic liver transplantation. Transplant Proc. 1987 Oct;19(5):4081–4082. [PubMed] [Google Scholar]
  14. Schmidt G. M., Horak D. A., Niland J. C., Duncan S. R., Forman S. J., Zaia J. A. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med. 1991 Apr 11;324(15):1005–1011. doi: 10.1056/NEJM199104113241501. [DOI] [PubMed] [Google Scholar]
  15. Singh N., Dummer J. S., Kusne S., Breinig M. K., Armstrong J. A., Makowka L., Starzl T. E., Ho M. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis. 1988 Jul;158(1):124–131. doi: 10.1093/infdis/158.1.124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Stratta R. J., Shaefer M. S., Cushing K. A., Markin R. S., Reed E. C., Langnas A. N., Pillen T. J., Shaw B. W., Jr A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg. 1992 Jan;127(1):55–64. doi: 10.1001/archsurg.1992.01420010065009. [DOI] [PubMed] [Google Scholar]
  17. Stratta R. J., Shaefer M. S., Cushing K. A., Markin R. S., Wood R. P., Langnas A. N., Reed E. C., Woods G. L., Donovan J. P., Pillen T. J. Successful prophylaxis of cytomegalovirus disease after primary CMV exposure in liver transplant recipients. Transplantation. 1991 Jan;51(1):90–97. doi: 10.1097/00007890-199101000-00014. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES